N/A
Completed N=547
A Study of the Patterns of Use of Etoricoxib in France (MK-0663-148)
Source: ClinicalTrials.gov NCT01572675 ↗Enrolled (actual)
547
Serious AEs
0.0%
Results posted
May 2016
Primary outcomePrimary: Number of Participants Demonstrating Proper Use of Arcoxia® and Celebrex® — 65; 118 Participants
Summary
This postmarketing study will examine the use of etoricoxib (Arcoxia®) in routine clinical practice in France as well as the use of celecoxib (Celebrex®).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants Demonstrating Proper Use of Arcoxia® and Celebrex® |
65; 118 | — |
| PRIMARY Reasons for Misuse of Arcoxia® and Celebrex® |
83; 114; 62; 19; 46; 13 | — |
| PRIMARY Indications for Which Arcoxia® and Celebrex® Were Prescribed |
113; 117; 105; 104; 13; 18 | — |
| PRIMARY Dosage of Arcoxia® and Celebrex® at Initiation |
151; 0; 107; 0; 1; 0 | — |
| PRIMARY Mean Dosage of Arcoxia® and Celebrex® During Treatment |
44.1; 221.9 | — |
| PRIMARY Number of Participants Requiring Dose Modification of Arcoxia® and Celebrex® |
1; 5; 42; 33; 1; 0 | — |
| PRIMARY Duration of Prescription for Arcoxia® and Celebrex® at Enrollment |
25.5; 38.1; 23.9; 41.7; 31.1; 34.0 | <0.001 sig |
| PRIMARY Total Duration of Treatment With Arcoxia® and Celebrex® |
85.2; 117.8; 472.9; 595.2; 122.4; 142.0 | — |
| PRIMARY Maximum Dosage Prescribed During Treatment With Arcoxia® and Celebrex® |
47.1; 48.4; 228.4; 242.7; 47.7; 236.5 | — |
| PRIMARY Reasons for Discontinuation of Treatment With Arcoxia® and Celebrex® |
140; 118; 16; 23; 31; 31 | — |
| PRIMARY Type of Arcoxia® and Celebrex® Use |
0; 2; 44; 47; 171; 147 | — |
| PRIMARY Type of Arcoxia® and Celebrex® Use According to Duration of Treatment |
0; 1; 1; 0; 24; 38 | <0.001 sig |
| SECONDARY Mean Body Mass Index (BMI) at Study Entry in Participants Treated With Arcoxia® and Celebrex® |
26.6; 27.1; 27.3; 27.0; 26.8; 27.1 | — |
| SECONDARY Mean Systolic and Diastolic Blood Pressure (BP) at Study Entry in Participants Treated With Arcoxia® and Celebrex® |
127.4; 130.9; 127.9; 128.4; 129.0; 128.2 | — |
| SECONDARY Blood Pressure at Study Entry in Participants Treated With Arcoxia® and Celebrex® |
3; 1; 5; 0; 4; 5 | 0.104 |
| SECONDARY Medical History of Participants Treated With Arcoxia® and Celebrex® |
37; 47; 34; 58; 84; 92 | 0.012 sig |
| SECONDARY Co-morbidities in Participants Treated With Arcoxia® and Celebrex® |
55; 44; 32; 62; 99; 94 | — |
| SECONDARY Significant Past Treatments Prior to Initiating Treatment With Arcoxia® or Celebrex® |
102; 75; 67; 118; 177; 185 | 0.701 |
| SECONDARY Medications Co-Prescribed at Study Entry in Participants Treated With Arcoxia® and Celebrex® |
15; 22; 3; 23; 37; 26 | — |
| SECONDARY Medications Co-Prescribed Over the Course of Follow-up With Arcoxia® and Celebrex® |
26; 38; 75; 65; 58; 55 | — |
| SECONDARY Number of Participants Treated With Other Agents Prior to Initiation of Arcoxia® and Celebrex® |
93; 86; 62; 102; 179; 164 | 0.049 sig |
| SECONDARY Number of Participants Switching to Another Treatment With the Same Reason for Prescription |
33; 29; 22; 22; 9; 6 | — |
| SECONDARY Number of Participants With Contraindications for Use of Arcoxia® |
36; 34; 70; 29; 32; 61 | — |
| SECONDARY Number of Participants Who Experienced at Least One Adverse Event |
10; 5 | 0.165 |
| SECONDARY Number of Participants Who Discontinued Study Drug Due to an Adverse Event |
6; 5 | — |
Eligibility Criteria
Inclusion Criteria
- Treatment-naive, discontinued the previous treatment course of etoricoxib or celecoxib at least 3 months previously or currently receiving continuous treatment with oral etoricoxib or celecoxib
- Consent to take part in the study
- Included in his/her physician's client base for at least 1 year
Exclusion Criteria
- Unable to receive follow-up over a year
- Included in an interventional trial
Data sourced from ClinicalTrials.gov (NCT01572675). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.